Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Advances in gene therapy have created a dynamic pipeline. A recent Datamonitor Healthcare report examines various trends in that pipeline, including vector types used, in vivo versus ex vivo approaches, and therapy areas being targeted.
Latest From Market Intelligence
EY executive survey yields insights into how digital technology is helping drive biopharma deal strategy and aiding companies to meet competitive challenges.
Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.
Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses retained a robust share of that global take and investors expect that trend to continue.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.